Evaluation of the physical properties and stability of two lipid drug delivery systems containing mefloquine
Stability data is used to determine the change the product has undergone over a certain time period at specific temperatures. In the present study, the physical stability characterized by size, pH and entrapment efficacy of mefloquine loaded liposomes and Pheroid™ vesicles were investigated. Size wa...
Uloženo v:
| Vydáno v: | International journal of pharmaceutics Ročník 409; číslo 1; s. 209 - 215 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Amsterdam
Elsevier B.V
16.05.2011
Elsevier |
| Témata: | |
| ISSN: | 0378-5173, 1873-3476, 1873-3476 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | Stability data is used to determine the change the product has undergone over a certain time period at specific temperatures. In the present study, the physical stability characterized by size, pH and entrapment efficacy of mefloquine loaded liposomes and Pheroid™ vesicles were investigated. Size was accurately determined by flow cytometry. Entrapment efficacy, after unentrapped drug was removed was successfully determined by UV-spectrophotometry. The formulations contained 0.5% (m/v) mefloquine and results showed that mefloquine interfered with the formation of lipid bilayer of the liposomes. Liposomes increased in size from 5.22
±
0.03
μm to 9.71
±
1.11
μm with accelerated stability and large aggregates were observed. A notable difference in stability testing of Pheroid™ vesicles was seen with no significant increase in size. Entrapment efficacy of 68.72
±
0.04% (5
°C), 67.45
±
2.92% (25
°C) and 67.45
±
2.92% (30
°C) were obtained at the different storage conditions. With these findings the mefloquine loaded Pheroid™ vesicles are stable and should be used investigated for the possible increase in efficacy and bioavailability and decrease toxicity. |
|---|---|
| Bibliografie: | http://dx.doi.org/10.1016/j.ijpharm.2011.01.050 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| ISSN: | 0378-5173 1873-3476 1873-3476 |
| DOI: | 10.1016/j.ijpharm.2011.01.050 |